Defibrotide lowers rates of veno-occlusive disease after transplant

02/24/2012 | DoctorsLounge.com

Defibrotide prophylaxis can reduce cases of hepatic veno-occlusive disease among patients younger than 18 undergoing hematopoietic stem cell transplantation, German researchers found. The study in The Lancet journal showed that 12% of patients who received the drug developed veno-occlusive disease 30 days after transplantation, compared with 20% in the control group.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX